Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

78P - Multiplex immunohistochemistry and digital pathology analysis examining the prevalence and prognostic value of tertiary lymphoid structures in early stage hormone positive, HER2 negative breast cancer

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Mairi Lucas

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101218-101218. 10.1016/esmoop/esmoop101218

Authors

M.W. Lucas1, C. Hurley2, Z. Kinsella2, C. Gonzalez3, C. Burke3, A. Rahman3, C. Jahangir3, J.P. Crown4, W.M. Gallagher5, C.M. Kelly6, D. O'Connor2

Author affiliations

  • 1 Blackrock Clinic, Blackrock/IE
  • 2 RCSI - Royal College of Surgeons in Ireland, Dublin/IE
  • 3 University College Dublin, Dublin/IE
  • 4 St Vincent's University Hospital, Dublin/IE
  • 5 National University of Ireland - University College Dublin, Dublin/IE
  • 6 Mater Private Network - Dublin, Dublin/IE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 78P

Background

Tertiary lymphoid structures (TLS) are ectopic lymphoid organs that arise in nonlymphoid tissue sites of chronic inflammation including tumours. The presence of TLS, has been associated with increased tumour antigen presentation and improved cytokine-mediated signalling activity against tumour cells. Due to this, TLS have been associated with favourable outcomes in a number of cancer types. There is limited data regarding the prevalence and prognostic implication of TLS in hormone positive, HER2-negative (ER+/HER2-) breast cancer.

Methods

Formalin-fixed paraffin embedded blocks from a cohort of 429 patients with early stage hormone positive/ HER2-negative breast cancer were used to construct a TMA with three x 1 mm cores per patient. Multiplex chromogenic immunohistochemistry staining was performed to stain for CD3+ T cells, CD20+ B cells and DCLamp + dendritic cells. Digital image analysis was performed using Qupath open source software.

Results

On the basis of staining with the TLS panel, samples could broadly be divided into three categories; immune cold with minimal immune infiltrate, T-cell only infiltrate and TLS defined by the presence of CD20+ B cells. TLS were seen in 14% (n=60) of patient samples which was similar to the rate of patients with a significant T-cell only immune infiltrate which was also 14% (n=60). The majority of samples had no infiltrate, comprising of 72% (n=312) of the cohort. The median CD3+ cells/mm2 in the entire cohort was 295mm2. When divided into these categories, there was no statistically significant difference in disease free survival (p value= 0.39) although there was a trend towards worse disease free survival in those with a high T-cell only infiltrate.

Conclusions

In contrast to other breast cancer subtypes, tumour infiltrating lymphocytes in ER+/HER2- breast cancer may be a poor prognositc feature. However this may be dependant on the subpopulation of immune infiltrate, with TLS presence perhaps differing from T-cell only infiltrate. Further research with larger cohorts would be required to investigate this further.

Legal entity responsible for the study

The authors.

Funding

Royal College of Surgeons Ireland (University) StAR MD programme.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.